サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1595030

前立腺がん診断薬の世界市場

Prostate Cancer Diagnostics

出版日
ページ情報
英文 89 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
前立腺がん診断薬の世界市場
出版日: 2024年11月22日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 89 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

前立腺がん診断薬の世界市場は2030年までに137億米ドルに達する見込み

2023年に58億米ドルと推定される前立腺がん診断薬の世界市場は、2023年から2030年にかけてCAGR 13.1%で成長し、2030年には137億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである予備検査は、CAGR 12.4%を記録し、分析期間終了までに100億米ドルに達すると予測されます。確認検査セグメントの成長率は、分析期間中CAGR 15.2%と推定されます。

米国市場は15億米ドルと推定、中国はCAGR16.9％で成長予測

米国の前立腺がん診断薬市場は2023年に15億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに33億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは16.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ9.2%と10.8%と予測されています。欧州では、ドイツがCAGR 10.0%で成長すると予測されています。

世界の前立腺がん診断薬市場- 主要動向と促進要因まとめ

前立腺がん診断薬とは何か、なぜ早期発見が不可欠なのか？

前立腺がん診断薬とは、男性の前立腺がんを検出、診断、モニタリングするために使用される方法と技術を指します。これらの診断法は、前立腺がんを早期に発見し、タイムリーな介入とより効果的な治療を可能にする上で極めて重要です。最も一般的な診断法には、前立腺特異抗原（PSA）血液検査、直腸指診（DRE）、MRIや超音波検査などの高度な画像診断技術があります。さらに、診断を確定し、がんの病期を決定するために、しばしば生検が行われます。前立腺がんは男性に最も多いがんの一つであることから、早期かつ正確な診断は、生存率を向上させ、治療計画を効果的に管理するために不可欠です。

特に高齢の男性や家族歴のある人など、リスクの高い人々の間で前立腺がんに対する意識が高まるにつれ、信頼性の高い診断の必要性はますます高まっています。前立腺がん診断薬は、正確でタイムリーな診断を提供することで、迅速な治療の開始に役立つだけでなく、治療後の病気の進行や再発のモニタリングもサポートします。早期発見により、治療の選択肢が広がり、死亡率を大幅に減らすことができます。人口の高齢化と前立腺がんの有病率の上昇に伴い、先進的な診断ツールに対する需要が高まっており、前立腺がん診断薬市場は現代のヘルスケアにとって極めて重要な要素となっています。

技術の進歩は前立腺がん診断薬をどう変えるか？

分子診断、画像診断、人工知能（AI）の技術進歩が前立腺がん診断薬に革命をもたらし、より正確で侵襲性が低く、迅速な診断を可能にしています。遺伝子検査やバイオマーカー検査などの分子診断検査は、前立腺がんに関連する特定の遺伝子変異やタンパク質マーカーを検出するために使用されるようになってきています。これらの検査は、患者のリスクレベルを決定するのに役立ち、個別化された治療決定の指針として使用され、臨床医ががんの個々の特徴に基づいて治療を調整することを可能にします。例えば、PCA3検査や4Kscore検査のような検査では、尿や血液を採取して特定のバイオマーカーを検出するため、リスク評価に役立ち、侵襲的な生検の必要性を減らすことができます。

マルチパラメトリックMRIやPETスキャンなどの高度な画像診断技術は、従来の方法よりも高い精度で前立腺がんを検出できる非常に詳細な画像を提供します。これらの技術により、生検でより正確な標的を絞り込むことが可能になり、効果的な治療計画を立てるために不可欠な、より正確ながんの病期分類に役立ちます。さらに、画像検査や遺伝子検査から得られる大規模なデータセットの分析にAIや機械学習アルゴリズムが使用されるようになり、人間の観察では見逃される可能性のあるパターンを特定することで診断精度が向上しています。AIを活用した診断は、リスク評価、病気の進行予測、治療への反応モニタリングにおいても有用であることが証明されつつあります。これらの技術が相まって、前立腺がん診断薬市場は変貌を遂げ、早期発見、個別化医療、患者転帰の改善を可能にしています。

なぜ患者や臨床家は先進的な前立腺がん診断薬を採用するようになってきているのでしょうか？

患者や臨床医は、より早期で正確な発見、侵襲性の低減、個別化された治療オプションの可能性から、先進的な前立腺がん診断薬を採用する傾向が強まっています。PSA検査やDREのような従来の診断法では、特異度や感度に限界があり、しばしば偽陽性や不必要な生検につながります。分子検査やMRIターゲット生検のような先進的な診断法は、がんのリスクや病期に関するより正確な情報を提供し、臨床医が患者の治療についてより良い情報に基づいた決定を下すことを可能にします。このことは、早期がんや進行の遅いがん患者にとって特に重要であり、即座に介入するのではなく、積極的なサーベイランスが可能になるため、過剰治療による副作用の可能性を減らすことができます。

患者にとって、先進的な診断法は、より信頼性の高い結果を提供し、侵襲的な処置の必要性を減らすことで安心感をもたらします。リキッドバイオプシーやバイオマーカーアッセイなどの非侵襲的検査は、がんの進行や再発を監視する侵襲性の低い方法を提供し、患者は最小限の不快感で病状を管理することができます。臨床的な観点からは、高度な診断はリスク層別化を促進し、腫瘍医は積極的な治療が必要な高リスク患者と、それほど集中的でないアプローチが有効な患者を識別することができます。前立腺がんに対する認識が高まるにつれ、高度な診断ツールの採用は患者ケアの標準となりつつあり、個別化された患者中心のヘルスケアに向けた幅広い動向と一致しています。

前立腺がん診断薬市場の成長を促進する要因とは？

前立腺がん診断薬市場の成長は、人口の高齢化、前立腺がんに対する意識の高まり、診断技術の進歩、精密医療に向けた動向など、いくつかの要因によってもたらされます。前立腺がんのリスクが高い高齢者人口が世界的に増加する中、ヘルスケアプロバイダーは早期発見と介入率の向上に努めており、診断薬に対する需要が高まっています。このような人口動態の変化により、特に前立腺がんの罹患率が高い国々では、定期的なスクリーニングとリスク評価が重視されるようになっています。さらに、認知度向上キャンペーンにより、より多くの男性が定期的な検診を受けるようになり、発見率の向上に寄与し、正確な診断の必要性が高まっています。

分子診断やAIなどの技術の進歩は、診断手順の正確性、迅速性、非侵襲性を向上させることにより、市場の成長をさらに促進しています。患者の遺伝子プロファイルやがんの特徴に基づいて治療の優先順位を決めるプレシジョン・メディシンの取り組みも、遺伝子やバイオマーカーに基づく診断の需要を加速しており、がん治療のより個別化されたアプローチを支えています。さらに、規制当局による革新的な診断ツールの承認も進んでおり、臨床医や患者にとってより利用しやすいものとなっています。ヘルスケアシステムが早期発見と個別化治療を優先させる中、これらの要因が総合的に前立腺がん診断薬市場の力強い成長を促し、がんとの闘いにおける重要な開発分野として位置付けられています。

セグメント

検査タイプ（予備検査、確認検査）

調査対象企業の例（全34件）

  • Abbott
  • Beckman Coulter, Inc.
  • BioMerieux, Inc.
  • Diasorin S.P.A.
  • Roche Diagnostics Corporation
  • Mdxhealth
  • Myriad Genetic, Inc.
  • Opko Health, Inc.
  • Siemens Healthineers USA
  • Ipsen Pharma

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP22652

Global Prostate Cancer Diagnostics Market to Reach US$13.7 Billion by 2030

The global market for Prostate Cancer Diagnostics estimated at US$5.8 Billion in the year 2023, is expected to reach US$13.7 Billion by 2030, growing at a CAGR of 13.1% over the analysis period 2023-2030. Preliminary Test, one of the segments analyzed in the report, is expected to record a 12.4% CAGR and reach US$10.0 Billion by the end of the analysis period. Growth in the Confirmatory Test segment is estimated at 15.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.5 Billion While China is Forecast to Grow at 16.9% CAGR

The Prostate Cancer Diagnostics market in the U.S. is estimated at US$1.5 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$3.3 Billion by the year 2030 trailing a CAGR of 16.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.2% and 10.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.0% CAGR.

Global Prostate Cancer Diagnostics Market - Key Trends & Drivers Summarized

What is Prostate Cancer Diagnostics, and Why is It Essential for Early Detection?

Prostate cancer diagnostics refers to the methods and technologies used to detect, diagnose, and monitor prostate cancer in men. These diagnostics are critical in identifying prostate cancer in its early stages, allowing for timely intervention and more effective treatment. The most common diagnostic methods include prostate-specific antigen (PSA) blood tests, digital rectal exams (DRE), and advanced imaging techniques like MRI and ultrasound. Additionally, biopsies are often used to confirm diagnosis and determine the stage of the cancer. Given that prostate cancer is one of the most common cancers among men, early and accurate diagnosis is essential to improving survival rates and managing treatment plans effectively.

The need for reliable diagnostics is increasingly important as awareness around prostate cancer grows, particularly among high-risk populations such as older men and those with a family history of the disease. By providing accurate and timely diagnoses, prostate cancer diagnostics not only help in initiating prompt treatment but also support monitoring of the disease's progression or recurrence after treatment. Early detection can lead to a wider range of treatment options and significantly reduce mortality rates. As the population ages and the prevalence of prostate cancer rises, demand for advanced diagnostic tools is increasing, making the prostate cancer diagnostics market a crucial component of modern healthcare.

How Are Technological Advancements Transforming Prostate Cancer Diagnostics?

Technological advancements in molecular diagnostics, imaging, and artificial intelligence (AI) are revolutionizing prostate cancer diagnostics, enabling more precise, less invasive, and faster diagnosis. Molecular diagnostic tests, such as genetic and biomarker testing, are increasingly used to detect specific genetic mutations or protein markers associated with prostate cancer. These tests help determine a patient’s risk level and may be used to guide personalized treatment decisions, allowing clinicians to tailor therapies based on the individual characteristics of the cancer. For example, tests like the PCA3 test and 4Kscore test use urine or blood samples to detect specific biomarkers, aiding in risk assessment and reducing the need for invasive biopsies.

Advanced imaging techniques, including multiparametric MRI and PET scans, provide highly detailed visuals that can detect prostate cancer with greater accuracy than traditional methods. These technologies allow for more precise targeting in biopsies and help in staging the cancer more accurately, which is essential for planning effective treatment. Additionally, AI and machine learning algorithms are now being used to analyze large datasets from imaging and genetic tests, enhancing diagnostic accuracy by identifying patterns that may be missed by human observation. AI-driven diagnostics are also proving valuable in risk assessment, predicting disease progression, and monitoring response to treatment. Together, these technologies are transforming the prostate cancer diagnostics market, enabling early detection, personalized care, and improved patient outcomes.

Why Are Patients and Clinicians Increasingly Adopting Advanced Prostate Cancer Diagnostics?

Patients and clinicians are increasingly adopting advanced prostate cancer diagnostics due to their potential for earlier and more accurate detection, reduced invasiveness, and personalized treatment options. Traditional diagnostics, such as PSA tests and DREs, have limitations in specificity and sensitivity, often leading to false positives or unnecessary biopsies. Advanced diagnostics, like molecular tests and MRI-targeted biopsies, provide more precise information on cancer risk and stage, enabling clinicians to make better-informed decisions about patient care. This is particularly important for patients with early-stage or slow-growing cancers, as it allows for active surveillance rather than immediate intervention, reducing potential side effects of overtreatment.

For patients, advanced diagnostics offer peace of mind by providing more reliable results and reducing the need for invasive procedures. Non-invasive tests, such as liquid biopsies and biomarker assays, offer a less intrusive way to monitor cancer progression or recurrence, allowing patients to manage their condition with minimal discomfort. From a clinical perspective, advanced diagnostics facilitate risk stratification, enabling oncologists to identify high-risk patients who require aggressive treatment and those who may benefit from less intensive approaches. As awareness around prostate cancer grows, the adoption of sophisticated diagnostic tools is becoming standard in patient care, aligning with a broader trend towards personalized and patient-centered healthcare.

What Factors Drive Growth in the Prostate Cancer Diagnostics Market?

The growth of the prostate cancer diagnostics market is driven by several factors, including the aging population, increased awareness of prostate cancer, advancements in diagnostic technology, and the trend towards precision medicine. With a growing global elderly population—who are at higher risk for prostate cancer—the demand for diagnostics is rising as healthcare providers strive to improve early detection and intervention rates. This demographic shift has intensified the focus on regular screenings and risk assessments, especially in countries with high prostate cancer prevalence. Additionally, increased awareness campaigns have encouraged more men to undergo routine screenings, contributing to greater detection rates and driving the need for accurate diagnostics.

Advancements in technology, such as molecular diagnostics and AI, are further propelling market growth by improving the accuracy, speed, and non-invasiveness of diagnostic procedures. Precision medicine initiatives, which prioritize treatments based on a patient’s genetic profile and cancer characteristics, have also accelerated demand for genetic and biomarker-based diagnostics, supporting a more personalized approach to cancer care. Moreover, regulatory agencies are increasingly approving innovative diagnostic tools, making them more accessible to clinicians and patients. As healthcare systems prioritize early detection and personalized treatment, these factors are collectively driving robust growth in the prostate cancer diagnostics market, positioning it as a key area of development in the fight against cancer.

SCOPE OF STUDY:

The report analyzes the Prostate Cancer Diagnostics market in terms of US$ Million by the following Test Type, and Geographic Regions/Countries:

Segments:

Test Type (Preliminary, Confirmatory)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • Abbott
  • Beckman Coulter, Inc.
  • BioMerieux, Inc.
  • Diasorin S.P.A.
  • Roche Diagnostics Corporation
  • Mdxhealth
  • Myriad Genetic, Inc.
  • Opko Health, Inc.
  • Siemens Healthineers USA
  • Ipsen Pharma

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Prostate Cancer Diagnostics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Prostate Cancer Globally Drives Demand for Advanced and Accurate Diagnostic Solutions
    • Increased Focus on Early Detection and Screening Spurs Market for Prostate-Specific Antigen (PSA) Testing
    • Growth in Personalized Medicine and Targeted Therapies Expands Demand for Genomic and Biomarker-Based Diagnostics
    • Advances in Imaging Technologies, Including MRI and PET Scans, Enhance Accuracy in Prostate Cancer Diagnosis
    • Increased Demand for Non-Invasive Testing Options Supports Development of Liquid Biopsy and Urine-Based Diagnostics
    • Growth in Awareness Campaigns and Screening Programs Elevates Market Demand for Accessible Diagnostic Tools
    • Expansion of AI and Machine Learning in Radiology Enhances Detection Accuracy and Reduces Diagnostic Errors
    • High Demand for Risk Stratification and Disease Progression Monitoring Fuels Use of Advanced Diagnostic Solutions
    • Rising Demand for Digital Pathology and Telemedicine Platforms Expands Accessibility of Prostate Cancer Diagnostics
    • Increased Focus on Minimally Invasive Biopsy Techniques Drives Adoption of MRI-Guided and Targeted Biopsies
    • Advances in Biomarker Discovery and Validation Strengthen Market for Predictive and Prognostic Testing
    • Growth of Immunohistochemistry (IHC) and Genetic Testing in Clinical Practice Expands Diagnostic Capabilities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Prostate Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Prostate Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Preliminary by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Preliminary by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Preliminary by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Confirmatory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Confirmatory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Confirmatory by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Prostate Cancer Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Prostate Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 11: USA Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 12: USA Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: USA 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 14: Canada Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 15: Canada Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: Canada 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • JAPAN
    • Prostate Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 17: Japan Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 18: Japan Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: Japan 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • CHINA
    • Prostate Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 20: China Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: China Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: China 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • EUROPE
    • Prostate Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 23: Europe Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: Europe Historic Review for Prostate Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: Europe 16-Year Perspective for Prostate Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • FRANCE
    • Prostate Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 29: France Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: France Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: France 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • GERMANY
    • Prostate Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Germany Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Germany 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 35: Italy Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Italy Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Italy 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Prostate Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 38: UK Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: UK Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: UK 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 41: Spain Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Spain Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Spain 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 44: Russia Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Russia Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Russia 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Rest of Europe Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Rest of Europe 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Prostate Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 51: Asia-Pacific Historic Review for Prostate Cancer Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Asia-Pacific 16-Year Perspective for Prostate Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Prostate Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 56: Australia Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Australia Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Australia 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • INDIA
    • Prostate Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 59: India Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: India Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: India 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 62: South Korea Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: South Korea Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: South Korea 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 65: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Rest of Asia-Pacific Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Rest of Asia-Pacific 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Prostate Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 68: Latin America Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 69: Latin America Historic Review for Prostate Cancer Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Latin America 16-Year Perspective for Prostate Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 74: Argentina Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Argentina Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Argentina 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 77: Brazil Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Brazil Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Brazil 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 80: Mexico Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Mexico Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Mexico 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 83: Rest of Latin America Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Rest of Latin America Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Rest of Latin America 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Prostate Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 86: Middle East Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 87: Middle East Historic Review for Prostate Cancer Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Middle East 16-Year Perspective for Prostate Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 92: Iran Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Iran Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Iran 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 95: Israel Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Israel Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Israel 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 98: Saudi Arabia Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Saudi Arabia Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Saudi Arabia 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 101: UAE Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: UAE Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: UAE 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 104: Rest of Middle East Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Rest of Middle East Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Rest of Middle East 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030
  • AFRICA
    • Prostate Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 107: Africa Recent Past, Current & Future Analysis for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Africa Historic Review for Prostate Cancer Diagnostics by Test Type - Preliminary and Confirmatory Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Africa 16-Year Perspective for Prostate Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Preliminary and Confirmatory for the Years 2014, 2024 & 2030

IV. COMPETITION